News & Updates

Show Multimedia Only

Topical chlorhexidine 1% reduces maternal, neonatal bacterial colonization

25 Jun 2026

Topical application of chlorhexidine 1% proves effective at reducing bacterial load in both mothers and neonates, according to the results of a randomized controlled trial.

Topical chlorhexidine 1% reduces maternal, neonatal bacterial colonization

25 Jun 2026

Oral probiotic supplementation may lower risk of preterm delivery recurrence

25 Jun 2026 by

Oral supplementation with probiotics containing Clostridium species may protect against the recurrence of spontaneous preterm delivery in high-risk pregnant women, according to a prospective, single-arm, trial conducted in Japan.

Oral probiotic supplementation may lower risk of preterm delivery recurrence

25 Jun 2026

Opioid systems influence ketamine’s antidepressant effect

25 Jun 2026

Complex interactions between glutamatergic, opioidergic, and GABAergic systems modulate the antidepressant effects of ketamine on cerebral blood flow (CBF) in patients with major depressive disorder (MDD), suggests a recent study.

Opioid systems influence ketamine’s antidepressant effect

25 Jun 2026

Letermovir safe to use for CMV prevention in paediatric HSCT recipients

25 Jun 2026 by

Real-life use of letermovir in paediatric recipients of haematopoietic stem cell transplant (HSCT) is generally safe and prevents the development of cytomegalovirus (CMV) disease, as shown in a study presented at ESPID 2026.

Letermovir safe to use for CMV prevention in paediatric HSCT recipients

25 Jun 2026

Lithium, antidepressant prevent relapse after ECT in patients with MDD

25 Jun 2026

A recent Delphi-based expert consensus has released guidelines on preventing relapse after a successful electroconvulsive therapy (ECT) for patients with major depressive disorder (MDD).

Lithium, antidepressant prevent relapse after ECT in patients with MDD

25 Jun 2026

Novel petrelintide shows promise for obesity treatment

25 Jun 2026 by

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

Novel petrelintide shows promise for obesity treatment

25 Jun 2026

Age-based ivermectin dosing safe, efficacious in children with scabies infection

24 Jun 2026 by

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.

Age-based ivermectin dosing safe, efficacious in children with scabies infection

24 Jun 2026

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

24 Jun 2026

Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.